Latest news for Luye Pharma Gr (OTC:LYPHF) Stock

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.

LUYE PHARMA GROUP LTD by Luye Pharma Group LTD.

Luye Pharma Group Ltd

Piper Sandler analyst Korinne Wolfmeyer maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Overweight and lowers the price target from $260 to $162.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on e.l.f. Beauty, Lowers Price Target to $162

The Company expects to wind down as quickly as possible after the sale, consistent with Michigan law and the Plan of Dissolution. Cash distributions to shareholders pursuant to the Plan of Dissolution will likely occur in two stages, with an initial distribution to shareholders of substantially all of the proceeds from the sale of the Bank to occur shortly following the closing.
The final distribution would occur following the resolution of all of the Company&#39;s obligations and liabilities in accordance with Michigan law and the Plan of Dissolution. It is anticipated that the earliest the final distribution would occur is six months following the closing of the sale of the Bank to EverBank.

Asset Sales

Sterling Bancorp Reveals Sale Of Sterling Bank And Trust, F.S.B. To EverBank Financial For Fixed Cash Consideration Of $261M; Adopts Plan Of Dissolution For Company Following Closing Of Sale

WIIM

IOBT

IO Biotech share are trading higher after announced promising data from the Phase 2 basket trial of IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's anti-PD-1 therapy KEYTRUDA at the 2024 ESMO Congress.

SpaceX CEO Elon Musk on Monday said there is a need for a new visible spectrum space telescope to replace or assist the Hubble space telescope.
What Happened: &#8220;Hubble is cool, but there needs to be a new visible spectrum space telescope with far larger aperture,&#8221; Musk said on social media platform X, formerly Twitter. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Hubble is cool, but there needs to be a new visible spectrum space telescope with far larger aperture
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1835590890116559257?ref_src=twsrc%5Etfw">September 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Hubble space telescope was launched to low-Earth orbit in 1990. Since then it has been orbiting Earth at an altitude of about 340 miles, capturing images. The Hubble has been serviced multiple times on orbit since, the latest of which was in 2009. It is now expected to last until 2030-2040.
Why It Matters: Shift4 Payments CEO and commercial astronaut Jared Isaacman previously proposed to service the telescope as part of his human spaceflight program called Polaris. The program is expected to embark on three human spaceflight missions with SpaceX.
However, NASA has yet to greenlight the proposal for Hubble to be serviced on a Polaris mission, National Public Radio (NPR) reported in May. 
Polaris Dawn, the first of up to three human spaceflight missions planned under the Polaris program, was launched last week by a SpaceX Falcon 9 launch vehicle. During the five-day mission, the crew, onboard a SpaceX Dragon spacecraft, touched a maximum altitude of over 870 miles and conducted the<a href="https://www.benzinga.com/news/24/09/40872104/polaris-dawn-returns-home-after-5-day-mission-including-first-commercial-spacewalk"> first-ever commercial spacewalk</a> on Thursday. 
The successful spacewalk and demonstration of the ability to touch high altitudes on the Polaris Dawn mission might help alleviate NASA&#8217;s concerns about the ability to service the Hubble telescope with a future Polaris mission using SpaceX hardware. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40849409/former-top-gear-host-james-may-thinks-a-vehicle-the-size-of-a-fiat-panda-but-styled-like-tesla-cyber?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Former Top Gear Host James May Thinks A Vehicle The Size Of A Fiat Panda But Styled Like Tesla Cybertruck Might Look ‘Fantastic'</a></li>
</ul>
Photo courtesy: NASA

SPACE

Tech

Elon Musk Says There Is A Need For A Space Telescope With 'Far Larger Aperture' Than Hubble

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Buy and maintains $70 price target.

Reiteration

IRON

HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target

INTC

Intel shares are trading higher following reports suggesting the company qualified for up to $3.5 billion in funding for US military chips.

Oppenheimer analyst Suraj Kalia initiates coverage on TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) with a Outperform rating and announces Price Target of $10.

Initiation

TLSI

Oppenheimer Initiates Coverage On TriSalus Life Sciences with Outperform Rating, Announces Price Target of $10

Although the digital asset market experienced a significant reversal last week, with inflows reaching $436 million, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is down to $58,700 in early Monday morning trading.
What Happened: After a prolonged period of outflows amounting to $1.2 billion, a shift in sentiment has reignited confidence in Bitcoin, which saw $436 million in inflows, ending a 10-day streak of outflows, <a href="https://blog.coinshares.com/volume-200-digital-asset-fund-flows-weekly-report-57a537a57c52">according</a> to Coinshares.
The turnaround is being attributed to shifting market expectations surrounding a potential 50 basis point interest rate cut by the Federal Reserve on Sep. 18, following remarks from former NY Federal Reserve President Bill Dudley.
Even so, Bitcoin is down 2% on Monday as markets try to price in the impact of an impending <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/09/40869076/advisors-brace-for-fed-rate-cuts-shifting-bond-strategies-to-balance-yield-an">interest rate cut</a> from the Federal Reserve.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), on the other hand, saw continued outflows, with $19 million exiting the asset, likely due to concerns about the profitability of Layer- 1 blockchains following Decun. It is down over 4% on Monday, trading around $2,300.
By contrast, Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), emerging as a rising star in the crypto space, recorded its fourth consecutive week of inflows, totaling $3.8 million. Solana is down 2.7%, trading around $132.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="http://Ouch! Harris, Trump-Themed Political Meme Coins Down 90%: What Happened To '4 More Years Of Catalysts'?">Ouch! Harris, Trump-Themed Political Meme Coins Down 90%: What Happened To &#8216;4 More Years Of Catalysts&#8217;?</a>
Why It Matters: CoinShares' data also highlights regional trends, with the U.S. leading the way, seeing $416 million in inflows, while Europe—especially Switzerland and Germany—contributed another $37.6 million combined. 
However, Canada bucked the trend with $18 million in outflows.
The inflows into Bitcoin and the growing preference for the cryptocurrency have been further supported by Bybit&#8216;s Q3 report, which emphasized Bitcoin&#8217;s dominance in investors&#8217; portfolios. 
Bitcoin now accounts for 27.5% of all crypto assets held by users, up from 25.7% in April 2024, largely due to the Bitcoin halving event and increasing institutional interest. 
The <a href="https://learn.bybit.com/crypto-insights/asset-allocation-q3-2024/">report</a> also noted that, although Ethereum remains a critical asset in many portfolios, its performance has lagged compared to Bitcoin and Solana, with investors showing a marked preference for Bitcoin as a more stable investment during uncertain market conditions.
Solana&#8217;s growth, particularly among retail investors, signals its growing influence as a viable alternative to Bitcoin and Ethereum. 
Bybit&#8217;s report highlighted that Solana has become the third-largest crypto asset held by users, with retail investors increasing their positions by 33.3% in July. 
The growing decentralized finance (DeFi) ecosystem on Solana has drawn considerable attention, bolstered by the platform's successful liquid staking and DeFi projects.
What&#8217;s Next: Looking ahead, Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 will dive into how these market trends, including Bitcoin&#8217;s dominance, Ethereum&#8217;s struggles, and Solana&#8217;s rise, will shape the future of digital assets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40857676/what-changed-federal-reserve-may-take-a-bigger-50-basis-points-rate-cut-bite-next-week-mar">&#8216;What Changed?&#8217; — Federal Reserve May Take A Bigger 50 Basis Points Rate Cut Bite Next Week, Market Odds Imply</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

Bitcoin Dips Below $59K Despite $436M Net ETF Inflows Last Week

Mining company BHP Group Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) has flagged an acute shortage of copper metal as global Big Techs, including Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Google parent Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and more, splurge on their artificial intelligence ambitions.
The growth of data centers and AI could boost global copper demand by 3.4 million tonnes a year by 2050, the Financial Times <a target="_blank" href="https://www.ft.com/content/da407b47-4133-470a-9574-508cee43e107" rel="noreferrer noopener">cites</a> BHP&#8217;s CFO Vandita Pant.
Pant told the FT that BHP Group expects global copper demand to reach 52.5 million tonnes annually by 2050, up 72% from 2021. Previously, the mining company had warned against a possible rise in copper prices as the demand outweighed supply.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/08/40441573/bhp-averts-strike-at-worlds-largest-copper-mine-stabilizes-chinese-copper-supply" rel="noreferrer noopener">BHP Averts Strike At World&#8217;s Largest Copper Mine, Stabilizes Chinese Copper Supply</a>
Copper is indispensable for industries pivotal to the zero-emission target, including power cables, electric vehicles, and solar farms. Therefore, a crisis in the metal could hamper the prospects of companies ranging from Microsoft, Google, and Amazon to EV companies like Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and more lest Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), fails to supply AI chips to the Big Techs due to the copper crisis.
<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40831930/copper-deficit-to-reach-4-million-tons-by-2030-analyst-predicts-mining-electrificat" rel="noreferrer noopener">JPMorgan analyst</a> Patrick Jones projected a four million metric tonnes copper deficit by 2030, courtesy of EVs and renewable energy demand. The analyst also blamed China&#8217;s weak demand, which accounts for over 50% of global copper demand.
BHP Group&#8217;s <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40577535/bhp-reports-13-7b-profits-eyes-additional-copper-expansion" rel="noreferrer noopener">copper production rose</a> 9% in fiscal 2024 for the second successive year, reaching 1.9 million tons. The average realized copper prices increased in fiscal 2024.
BHP Group has snapped a 50% stake in Argentina&#8217;s&nbsp;Filo del Sol and&nbsp;Josemaria&nbsp;copper projects, which have the potential to help accomplish a 70% increase in global copper demand by 2050.
BHP Group <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39816439/bhp-shares-trade-higher-as-mining-giant-confirms-record-outputs-for-copper-iron-ore" rel="noreferrer noopener">expects the production</a> to grow by another 4% in fiscal 2025, reaching 1.85 million tons–2.05 million tons.
BHP Group&#8217;s stock has been down close to 14% in the last 12 months. Investors can gain exposure to the stock through the Avantis International Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVDTHE#NYSE">AVDTHE</a>) and Dimensional International Core Equity Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFAI#NYSE">DFAI</a>).
Price Action: BHP stock is up 0.42% at $53.11 premarket at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition" target="_blank" rel="noreferrer noopener">BHP To Unlock South American Copper Riches: Partners With Lundin For Filo Acquisition</a></li>
</ul>
Benzinga Mining is the bridge between mining companies and retail investors. Reach out to <a href="mailto:licensing@benzinga.com" target="_blank" rel="noreferrer noopener">licensing@benzinga.com</a> to get started!
Photo via Shutterstock

Commodities

Media

AMZN

AVDTHE

DFAI

GOOG

GOOGL

MSFT

NVDA

TSLA

BHP Group Sounds Alarm on Copper Supply, AI and EV Growth Could Drive Prices Soaring: Report

Morgan Stanley analyst Bob Huang maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Overweight and raises the price target from $260 to $300.

Morgan Stanley Maintains Overweight on Progressive, Raises Price Target to $300

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) with a Buy and maintains $55 price target.

BCYC

HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $55 Price Target

ZNTL

Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA lifted the partial clinical hold on studies of azenosertib and remains on track to meet all previously disclosed data guidance for the remainder of 2024.

Morgan Stanley analyst Matthew Harrison maintains IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) with a Overweight and raises the price target from $4 to $6.

Morgan Stanley Maintains Overweight on IO Biotech, Raises Price Target to $6

Morgan Stanley analyst Daniel Kutz upgrades Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) from Equal-Weight to Overweight and maintains the price target from $175 to $175.

Upgrades

GTLS

Morgan Stanley Upgrades Chart Industries to Overweight, Maintains Price Target to $175

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Buy and maintains $46 price target.

ITOS

HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $46 Price Target

RLAY

Relay Therapeutics shares are trading are trading higher after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $18 to $19.

The Dow Jones index closed higher by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">P3 Health Partners</h3>
<ul>
<li>The Trade: P3 Health Partners Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) 10% owner CPF III-A PT SPV, LLC <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 160,000 shares</a> at an average price of $0.51. To acquire these shares, it cost around $81,552.</li>
<li>What's Happening: On Aug. 7, P3 Health Partners posted downbeat quarterly earnings.</li>
<li>What P3 Health Partners Does: P3 Health Partners Inc is a patient-centered and physician-led population health management company.</li>
</ul>
<h3 class="wp-block-heading">XWELL</h3>
<ul>
<li>The Trade: XWELL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) Director Gaelle Sandra Wizenberg <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,201 shares at </a> an average price of $1.65. To acquire these shares, it cost around $1,987.</li>
<li>What's Happening: On Sept. 5, XWELL named Ezra T. Ernst as CEO.</li>
<li>What XWELL Does: XWELL Inc is a health and wellness holding company.</li>
</ul>
<h3 class="wp-block-heading">ThredUp</h3>
<ul>
<li>The Trade: ThredUp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) Director Noam Paransky <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 40,008 shares</a> at an average price of $0.81. The insider spent around $32,407 to buy those shares.</li>
<li>What's Happening: On Aug. 5, ThredUp reported worse-than-expected second-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>What ThredUp Does: ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

PIII

TDUP

XWEL

ThredUp And 2 Other Stocks Under $2 Executives Are Buying

iTeos Therapeutics shares are trading lower. The company announced follow-up interim data from GALAXIES Lung-201,

The acquisition includes&nbsp;BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey, including certain patient service centers (PSCs), customer contracts and operating assets, which currently generate approximately $100 million in annual revenue.

Health Care

General

Laboratory Corporation Of America Holdings

Labcorp Has Completed The Acquisition Of Select Assets Of And Opko Health's Bioreference Health For $237.5M

EXAS

Exas Science shares are trading higher after the company announced data for its blood-based colorectal cancer screening test.

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group Ltd. has announced that their new Parkinson's disease treatment, Jinyouping (...

Luye Pharma's New Parkinson's Drug Approved in China

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group Ltd. announced that their drug LY03010, aimed at treating schizophrenia and s...

Luye Pharma's LY03010 Clears FDA Inspection

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group Ltd. has announced a significant deal where an investor will inject up to RMB...

Luye Pharma Group Announces Major Investment Deal

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group Ltd. has announced that their product ERZOFRI (paliperidone palmitate), an ex...

Luye Pharma's ERZOFRI Wins FDA Approval

Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million, and up to more than $2 billion in milestones.

Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal

Week In Review: ImmuneOnco Out-Licenses 2 Antibodies In $2 Billion Deal

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group Ltd. has announced the approval to begin clinical trials in China for LY03020...

Luye Pharma's Breakthrough Drug Enters Clinical Trials

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group Ltd. has successfully completed the initial phase of a significant investment...

Luye Pharma Group Completes Key Investment Phase

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group Ltd. has scheduled a board meeting for August 28, 2024, to review and approve...

Luye Pharma Sets Date for Financial Results Review

Luye Pharma Group (HK:2186) has released an update. Luye Pharma Group Ltd. has reported a robust increase in its financial performance for the firs...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Luye Pharma Gr

News

Latest news for Luye Pharma Gr (OTC:LYPHF) Stock